FDA pushes public trial transparency

The Food and Drug Administration is pressing drug companies and researchers to make overdue trial results public, widening a transparency campaign that now reaches thousands of studies. (fda.gov) On March 30, 2026, the agency sent messages to more than 2,200 sponsors and researchers tied to more than 3,000 registered clinical trials that appear to be missing required results or stuck in quality-control review at ClinicalTrials.gov. The Food and Drug Administration said the outreach seeks voluntary compliance. (fda.gov) ClinicalTrials.gov is the federal registry where many drug, biologic and device trials must list basic study details and later post summary results. Under the Food and Drug Administration Amendments Act of 2007 and its final rule, certain “applicable clinical trials” generally must submit results within one year of the trial’s primary completion date. (clinicaltrials.gov) The Food and Drug Administration said companies and researchers “often fail” to disclose negative trial results, leaving gaps in the public record and skewing the picture of how often drug programs succeed or fail. The National Library of Medicine, which runs ClinicalTrials.gov, separately notes that results are not required for every study, including many observational studies and some older trials. (fda.gov) (clinicaltrials.gov) The push follows a second transparency move aimed at the drug approval process itself. On July 10, 2025, the Food and Drug Administration published more than 200 complete response letters, the decision letters that tell companies why a drug or biologic application was not approved in its current form. (fda.gov) Those letters covered applications submitted between 2020 and 2024. On September 5, 2025, the agency said it would begin releasing future complete response letters promptly after they are sent to sponsors and posted another 89 previously unpublished letters tied to pending or withdrawn applications. (fda.gov 1) (fda.gov 2) A complete response letter is not a final rejection of a drug forever. It is the Food and Drug Administration’s formal notice that an application cannot be approved yet because of problems such as safety, effectiveness, manufacturing or bioequivalence. (fda.gov 1) (fda.gov 2) The agency says publishing those letters can show other developers where applications commonly fail and reduce guesswork for investors, doctors and patients. Some industry lawyers have warned that broader disclosure could also expose confidential business information or create legal disputes over what should be redacted. (fda.gov) (sidley.com) BioSpace reported on April 14, 2026, that internal Food and Drug Administration data showed about 30% of trials required to report results had not done so. The agency’s latest notices do not impose new rules, but they signal that missing trial data and unpublished review letters are now both targets of the same disclosure drive. (biospace.com) (fda.gov)